Recent studies have focused on the overlap of GLP|GIP|GCGR activator therapies and dopaminergic communication. While GCGR activators are increasingly employed for managing type 2 diabetes, their unexpected impacts on reinforcement circuits, specifically influenced by dopamine pathways, are receiving substantial focus. This article provides a summar